Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Airfinity; Chart: Andrew Witherspoon/Axios

The Biden administration took its biggest step yet toward becoming a global supplier of coronavirus vaccines, announcing that it would export 60 million AstraZeneca doses over the next several weeks.

Why it matters: President Biden has been under intense global scrutiny for his "Americans first" approach. Alone among the four major producers, the U.S. has kept nearly its entire supply up to now.

  • The biggest symbol of Washington's "vaccine nationalism" had been the stockpiling of the AstraZeneca vaccine — not approved and not needed in the U.S., but crucial to many countries' rollouts.
  • A senior administration official told reporters tonight that just 10 million doses were waiting to be distributed (much lower than had been reported), while another 50 million doses would be ready by June.

Those doses will be exported around the world, pending an FDA safety review, but the White House says no decisions have been made as to which countries will receive them.

  • India could be near the top of the list given the terrifying outbreak there, though the White House says Prime Minister Narendra Modi did not request doses in a call with Biden today.
  • So too could Mexico, which has turned to Russia and China in search of vaccines despite bordering one of the world's largest producers.
Expand chart
Note: This map represents the total number of vaccines administered, not people vaccinated; Data: Our World in Data; Map: Danielle Alberti/Axios

Breaking it down: While relatively small compared to the 231 million doses the U.S. has already administered, 60 million doses would be a major boost to the severely strained global supply.

  • The COVAX initiative, the primary source of vaccines for dozens of lower-income countries, has thus far only distributed 45 million doses globally.
  • Still, now that Biden has shown he's willing to export the vaccine the U.S. isn't using, the obvious next question is when he'll allow exports of the ones it is: Pfizer, Moderna and Johnson & Johnson.

What to watch: Nearly every U.S. adult who wants a vaccine will likely have had one within the next two to three weeks, Axios' Caitlin Owens reports.

  • And as demand begins to wane, supply should continue to ramp up. Pfizer, Moderna, J&J and AstraZeneca still owe the U.S. hundreds of millions of doses (more still if Biden exercises additional purchase options).
  • Biden will face international pressure and public health imperatives to share those doses with the world. He has said that he hopes to do so once the U.S. has a "surplus" but offered no clarity as to what qualifies as a surplus or where the doses will go.
  • On the one hand: The Biden administration has emphasized the need for caution and flexibility at home, citing possible production disruptions, the likely need for booster shots and the possibility of vaccinating children.
  • On the other: Secretary of State Tony Blinken has said the U.S. will become "the world leader in helping to make sure that the entire world gets vaccinated."

The bottom line: Even as the U.S. puts billions of dollars toward that goal, it has been unwilling to tap the biggest asset at Biden's disposal: the doses streaming out of U.S. factories each week.

Go deeper

Apr 26, 2021 - World

European Commission sues AstraZeneca for vaccine shortages

Photo: Thierry Monasse/Getty Images

The European Commission has launched legal proceedings against AstraZeneca for providing only a third of the supply of coronavirus vaccines agreed to in its contract, a spokesperson confirmed Monday.

Why it matters: It's the latest in a string of controversies related to the European Union's vaccine rollout, which has been plagued by supply shortages, a slow pace of distribution, and concerns about potential rare blood clots linked to AstraZeneca and Johnson & Johnson.

Apr 26, 2021 - Health

Sanofi to manufacture 200 million Moderna COVID vaccines in U.S.

Photo: Ty O'Neil/SOPA Images/LightRocket via Getty Images

Sanofi announced Monday it will manufacture up to 200 million doses of Moderna's COVID-19 vaccine at its site in Ridgefield, New Jersey, from September.

Why it matters: The agreement between Sanofi and Moderna should not only boost the U.S. coronavirus vaccine rollout, it should also help global efforts as the doses will likely be exported.

Apr 26, 2021 - Health

Poll: 73% of unvaccinated Americans say they won't take the J&J shot

An Army nurse holds a vial of the Johnson & Johnson vaccine at the FEMA-supported COVID-19 vaccination site at Valencia State College on April 25. Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

About 3 in 4 unvaccinated adult Americans are unwilling to get the Johnson & Johnson coronavirus vaccine, a Washington Post-ABC News poll out Monday indicates.

Why it matters: Less than half of all U.S. adults polled said they thought the J&J shot — which presents fewer logistical challenges than the more temperature-controlled, two-shot Pfizer and Moderna vaccines — is safe.